Validation of dose distribution computation on sCT images generated from MRI scans by Philips MRCAT
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F19%3A10398628" target="_blank" >RIV/00179906:_____/19:10398628 - isvavai.cz</a>
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=kbHGimSA3S" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=kbHGimSA3S</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.rpor.2019.02.001" target="_blank" >10.1016/j.rpor.2019.02.001</a>
Alternative languages
Result language
angličtina
Original language name
Validation of dose distribution computation on sCT images generated from MRI scans by Philips MRCAT
Original language description
Aim: To evaluate calculation of treatment plans based on synthetic-CT (sCT) images generated from MRI. Background: Because of better soft tissue contrast, MR images are used in addition to CT images for radiotherapy planning. However, registration of CT and MR images or repositioning between scanning sessions introduce systematic errors, hence suggestions for MRI-only therapy. The lack of information on electron density necessary for dose calculation leadsto sCT (synthetic CT) generation. This work presents a comparison of dose distribution calculated on standard CT and sCT. Materials and methods: 10 prostate patients were included in this study. CT and MR images were collected for each patient and then water equivalent (WE) and MRCAT images were generated. The radiation plans were optimized on CT and then recalculated on MRCAT and WE data. 2D gamma analysis was also performed. Results: The mean differences in the majority of investigated DVH points were in order of 1% up to 10%, including both MRCAT and WE dose distributions. Mean gamma pass for acceptance criteria 1%/1 mm were greater than 82.5%. Prescribed doses for target volumesand acceptable doses for organs at risk were met in almost all cases. Conclusions: The dose calculation accuracy on MRCAT was not significantly compromised in the majority of clinical relevant DVH points. The introduction of MRCAT into practise would eliminate systematic errors, increase patients' comfort and reduce treatment expenses. Institutions interested in MRCAT commissioning must, however, consider changes to established workflow. (C) 2019 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Reports of Practical Oncology and Radiotherapy
ISSN
1507-1367
e-ISSN
—
Volume of the periodical
24
Issue of the periodical within the volume
2
Country of publishing house
PL - POLAND
Number of pages
6
Pages from-to
245-250
UT code for WoS article
000461452700017
EID of the result in the Scopus database
2-s2.0-85062042237